Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients

NCT00771953 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT00771953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00771953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
December 31, 2014
Enrollment
109 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non small cell lung cancer